02 May 2003
Regulation of microglial functions by PARP-1 – a target for therapeutic interventions?
O. UllrichMed Sci Monit 2003; 9(1): 73-0 :: ID: 15216
Abstract
During the last decade of neurobiological research, it has become evident that inflammatory pathways in the CNS, involving a network of non-neuronal and neuronal cells, are important contributors to the onset and progress of several major neurodegenerative diseases [1]. One major component of inflammatory neuronal damage is the transformation of microglia cells into activated immunoeffector cells and their migration towards the sites of injury, where they produce large amounts of toxic cytokines and oxygen radicals [2]. During this transformation, PARP-1 is highly activated and enables microglia cells to cope with oxidative challenges, in particular by upregulating the proteasomal degradation of damaged nuclear proteins [3]. Besides the initiation of intracellular defense pathways, PARP-1-dependent signalling is also involved in regulating specific functions of activated microglia: It regulates the expression of the integrin CD11a through interaction with the translocated NF-kB and therefore strongly controls migration into the regions of neuronal injury [4]. Furthermore, it enhances the production of the proinflammatory cytokine TNF-alpha and of the antiinflammatory endocannabinoid 2-AG, which in turn downregulates the release of nitric oxide. We are therefore considering PARP-1 to be a multiple player in the concert of neuroinflammation, in which therapeutic interventions directed against PARP-1 would affect both neuronal and non-neuronal components. Downregulation of PARP-1 specifically in microglia almost completely abrogates microglial migration and prevents neurons from secondary damage. This renders PARP-1 a target for therapeutic strategies in neurodegenerative diseases, in which pathological microglia activation and migration play a major role. References: 1.Floyd RA et al: Free Radic Biol Med, 1999; 26: 1346-1355 2.Mabuchi T et al: Stroke, 2000; 31(7): 1735-1743 3.McGeer PL et al: Brain Res Rev, 1995; 21: 195-218 4.Ullrich O et al: FASEB J, 2001; 15: 1460-1462 5.Ullrich O et al: Nature Cell Biol, 2001; 3: 1035-1042
Keywords: neuroinflammation, Microglia, Cytokines, Integrins
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952